ReviewCirculation research2013
Adrenergic nervous system in heart failure: pathophysiology and therapy.
Review in Circulation research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 329 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
329 citing papers in PubMed, 2 syntheses or guidelines pooled it, 586 citations in OpenAlex.
- Effects of Adrenergic Receptor Stimulation on Human Hemostasis: A Systematic Review.Advances in experimental medicine and biology · 2023Pooled it
- Pooled it
- Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure.Circulation. Heart failure · 2023Trial
- The bioequivalence of fixed-dose combination tablets of bisoprolol and ramipril and its drug-drug interaction potential.Clinical and translational science · 2022Trial
- Carvedilol Does Not Improve Exercise Performance in Fontan Patients: Results of a Crossover Trial.Pediatric cardiology · 2021Trial
- Epac1 Functions as a Central Cardioprotective cAMP Effector During Ischemic and β-adrenergic Preconditioning.Cardiovascular drugs and therapy · 2026Article
- Behavioral and electrophysiological evaluation of the anesthetic therapeutic window of thyme essential oil in tambaqui (Colossoma macropomum).Fish physiology and biochemistry · 2026Article
- The solute carrier transporter SLCO5A1 as a novel therapeutic target for the treatment of myocardial infarction-induced heart failure.Acta pharmacologica Sinica · 2026Article
- Discovery of a peripherally restricted αCell reports. Medicine · 2026Article
- Circadian regulation of cardiovascular function: from physiology to clinical implications.Genome medicine · 2026Review
- Effect of the gut microbiota metabolite phenylacetylglycine on cardiac CaBiophysical reports · 2026Article
- Sex-Specific Prognostic Value of Left Atrioventricular Coupling Index in Acute Coronary Syndrome: Insights From Artificial Intelligence-Enhanced 3-Dimensional Echocardiography.Journal of the American Heart Association · 2026Article
- Phosphoinositide Depletion and Compensatory Phospho-Signaling in Angiotensin II-Induced Heart Disease.Circulation research · 2026Article
- Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Optimization and evaluation of different fast acting tablet formulations containing bisoprolol fumarate.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- PET imaging of cardiac sympathetic nervous system dysfunction using meta-[European journal of nuclear medicine and molecular imaging · 2026Article
- The prognostic impact of beta blockers in ischemic heart failure: time for a paradigm shift?Heart failure reviews · 2026Review
- Age-dependent Transcriptional Programs Distinguish Pediatric from Adult Dilated Cardiomyopathy.medRxiv : the preprint server for health sciences · 2026Article
- β-Adrenergic Receptors: Not Always Outside-In.Physiology (Bethesda, Md.) · 2026Review
- A Translational Model of MASLD-Associated HFpEF Defines Mitochondrial Dysfunction and Cardiac Plasticity During Disease Progression and Regression.bioRxiv : the preprint server for biology · 2026Article
269 more citing papers are in PubMed but not listed here.
Corrections and comments
- Correction · 2016-08-04Euphemisms for Plagiarism · Plagiarism of Text ·
- Erratum issuedCorrection.2016
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Heart failure (HF), the leading cause of death in the western world, develops when a cardiac injury or insult impairs the ability of the heart to pump blood and maintain tissue perfusion. It is characterized by a complex interplay of several neurohormonal mechanisms that become activated in the syndrome to try and sustain cardiac output in the face of decompensating function. Perhaps the most prominent among these neurohormonal mechanisms is the adrenergic (or sympathetic) nervous system (ANS), whose activity and outflow are enormously elevated in HF. Acutely, and if the heart works properly, this activation of the ANS will promptly restore cardiac function. However, if the cardiac insult persists over time, chances are the ANS will not be able to maintain cardiac function, the heart will progress into a state of chronic decompensated HF, and the hyperactive ANS will continue to push the heart to work at a level much higher than the cardiac muscle can handle. From that point on, ANS hyperactivity becomes a major problem in HF, conferring significant toxicity to the failing heart and markedly increasing its morbidity and mortality. The present review discusses the role of the ANS in cardiac physiology and in HF pathophysiology, the mechanisms of regulation of ANS activity and how they go awry in chronic HF, methods of measuring ANS activity in HF, the molecular alterations in heart physiology that occur in HF, along with their pharmacological and therapeutic implications, and, finally, drugs and other therapeutic modalities used in HF treatment that target or affect the ANS and its effects on the failing heart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.